These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19423276)

  • 41. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
    Agunbiade TA; Zaghlol RY; Barac A
    Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
    Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.
    Amigoni M; Giannattasio C; Fraschini D; Galbiati M; Capra AC; Madotto F; Cesana F; Jankovic M; Masera G; Mancia G
    Pediatr Blood Cancer; 2010 Dec; 55(7):1343-7. PubMed ID: 20589666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy.
    Cheung YF; Hong WJ; Chan GC; Wong SJ; Ha SY
    Heart; 2010 Jul; 96(14):1137-41. PubMed ID: 20511624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines.
    Guimaraes-Filho F; Tan D; Braga J; Rodrigues A; Waib P; Matsubara B
    Am J Cardiol; 2007 Oct; 100(8):1303-6. PubMed ID: 17920375
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heart Failure Therapies for End-Stage Chemotherapy-Induced Cardiomyopathy.
    Mukku RB; Fonarow GC; Watson KE; Ajijola OA; Depasquale EC; Nsair A; Baas AS; Deng MC; Yang EH
    J Card Fail; 2016 Jun; 22(6):439-48. PubMed ID: 27109619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.
    Castelli G; Fornaro A; Ciaccheri M; Dolara A; Troiani V; Tomberli B; Olivotto I; Gensini GF
    Circ Heart Fail; 2013 Sep; 6(5):913-21. PubMed ID: 23888044
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy.
    Hung OY; Brown JR; Dai T; Easley KA; Flowers CR; Parashar S
    BMJ Open; 2015 Oct; 5(10):e008350. PubMed ID: 26443656
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up].
    Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P
    Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors.
    Abosoudah I; Greenberg ML; Ness KK; Benson L; Nathan PC
    Pediatr Blood Cancer; 2011 Sep; 57(3):467-72. PubMed ID: 21280201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy.
    Motoki H; Koyama J; Nakazawa H; Aizawa K; Kasai H; Izawa A; Tomita T; Miyashita Y; Kumazaki S; Takahashi M; Ikeda U
    Eur Heart J Cardiovasc Imaging; 2012 Jan; 13(1):95-103. PubMed ID: 21926409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors.
    Shahzad MA; Ishtiaq R; Zahid U; Anwer F
    BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27852680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy.
    Kumar S; Marfatia R; Tannenbaum S; Yang C; Avelar E
    Tex Heart Inst J; 2012; 39(3):424-7. PubMed ID: 22719160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cardiotoxicity of anthracyclines].
    Laurent S; Colbert N; Izrael V; Motte G
    Ann Med Interne (Paris); 1984; 135(6):464-72. PubMed ID: 6391323
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
    Rathe M; Carlsen NL; Oxhøj H
    Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective effects of spironolactone against anthracycline-induced cardiomyopathy.
    Akpek M; Ozdogru I; Sahin O; Inanc M; Dogan A; Yazici C; Berk V; Karaca H; Kalay N; Oguzhan A; Ergin A
    Eur J Heart Fail; 2015 Jan; 17(1):81-9. PubMed ID: 25410653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk assessment and management of anthracycline and HER2 receptor inhibitor-induced cardiomyopathy.
    Jahangir E; Shah S; Shum K; Baxter C; Fitzpatrick JD; Cole J; Gilliland Y; Polin NM
    South Med J; 2015 Feb; 108(2):71-8. PubMed ID: 25688890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.